Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 3, Mars 2003
Page(s) 327 - 336
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003193327
Publié en ligne 15 mars 2003
  1. Demoly P, Messaad D, Benahmed S, et al. Les réactions immunoallergiques d’origine médicamenteuse: données épidémiologiques et cliniques. Therapie 2000; 55: 13–21. [Google Scholar]
  2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200–5. [Google Scholar]
  3. Imb JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Therapie 1999; 54: 21–7. [Google Scholar]
  4. Bigby M, Jick S, Jock H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358–63. [Google Scholar]
  5. Smith JW, Johnson JEIII, Cliff LE. Studies on the epidemiology of adverse drug reactions. II. An evaluation of penicillin allergy. N Engl J Med 1966; 274: 998–1002. [Google Scholar]
  6. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children. Arch Dermatol 2000; 136: 849–54. [Google Scholar]
  7. Burke P, Burne SR. Allergy associated with ciprofloxacin. Br Med J 2000; 320: 679. [Google Scholar]
  8. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621–8. [Google Scholar]
  9. Laxenaire MC. Épidémiologie des réactions anaphylactoides peranesthésiques. Quatrième enquête multicentrique (juillet 1994-décembre 1996). Ann Fr Anesth Reanim 1999; 18: 796–809. [Google Scholar]
  10. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994; 331: 1272–85. [Google Scholar]
  11. Lenler-Petersen P, Hansen D, Andersen M, et al. Drugrelated fatal anaphylactic shock in Denmark 1968- 1990. A study based on notifications to the Committee on Adverse Drug Reactions. J Clin Epidemiol 1995; 48: 1185–8. [Google Scholar]
  12. Sheikh A, Alves B. Hospital admissions for acute anaphylaxis: time trend study. Br Med J 2000; 320: 1441. [Google Scholar]
  13. International Rheumatic Fever Study Group. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. Lancet 1991; 337: 1308–10. [Google Scholar]
  14. Lafaye P, Lapresles C. Fixation of penicilloyl groups to albumin and appearance of antipenicilloyl antibodies in penicillin-treated patients. J Clin Invest 1988; 82: 7–12 [Google Scholar]
  15. Haddi E, Charpin D, Tafforeau M, et al. Atopy and systemic reactions to drugs. Allergy 1990; 45: 236–9. [Google Scholar]
  16. Romano A, De Santis A, Romito A, et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 1998; 80: 433–7. [Google Scholar]
  17. Kowalski ML, Woszczek G, Bienkiewicz B, Mis M. Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998; 28: 1353–8. [Google Scholar]
  18. Vittorio CC, Muglia JJ. Anticonvulsiviant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285–90. [Google Scholar]
  19. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670–4. [Google Scholar]
  20. Asero R. Detection of patients with multiple drug allergy syndrome by elective tolerance tests. Ann Allergy Asthma Immunol 1998; 80: 185–8. [Google Scholar]
  21. Khoury L, Warrington R. The multiple drug allergy syndrome: a matchedcontrol retrospective study in patients allergic to penicillin. J Allergy Clin Immunol 1996; 98: 462–4. [Google Scholar]
  22. Zanni MP, von Greyerz S, Scnyder B, Wendland T, Pichler WJ. HLA-restricted, processing- and metabolism independent pathway of drug recognition by human αβ T lymphocytes. J Clin Invest 1998; 102: 1591–8. [Google Scholar]
  23. Rieder MJ, Uetrcht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro rechallenge with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286–9. [Google Scholar]
  24. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179–84. [Google Scholar]
  25. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprimsulphamethoxazole in HIVinfected patients. AIDS 1994; 8: 333–7. [Google Scholar]
  26. Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255–8. [Google Scholar]
  27. Naisbitt DJ, Vilar J, Stalford A, et al. Plasma cysteine and decreased reduction of nitroso sulphamethoxazole with HIV infection. AIDS Res Hum Retrovir 2000; 16: 1929–38. [Google Scholar]
  28. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathion deficiency in symptom free HIVseropositive individuals. Lancet 1989; 334: 1294–8. [Google Scholar]
  29. Roujeau JC. Toxidermies médicamenteuses: quelques nouveautés. Rev Fr Allergol Immunol Clin 2002; 42: 71–4. [Google Scholar]
  30. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHCdependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100: 136–41. [Google Scholar]
  31. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462–72. [Google Scholar]
  32. Zanni MP, von Greyerz S, Schnyder B, Wendland T, Pichler WJ. HLAunrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T cell clones. Immunol Int 1998; 10: 507–15. [Google Scholar]
  33. Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in druginduced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433–41. [Google Scholar]
  34. Zanni MP, Mauri-Hellweg D, Brander C, et al. Characterization of lidocaine specific T cells. J Immunol 1997; 158: 1139–48. [Google Scholar]
  35. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3. [Google Scholar]
  36. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31: 1198–408. [Google Scholar]
  37. Blanca M, Posadas SJ, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous drug reactions. Allergy 2000; 55: 998–1004. [Google Scholar]
  38. Posadas SJ, Leyva L, Torres MJ, et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reactions. J Allergy Clin Imunol 2000; 106: 769–76. [Google Scholar]
  39. Weltzien HU, Padovan E. Molecular features of penicillin allergy. J Invest Dermatol 1998; 110: 203–6. [Google Scholar]
  40. Barbaud A, Béné MC, Reichert-Penetrat S, Jacquin-Petit MA, Schmutz JL, Faure GC. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998; 134: 1040–1. [Google Scholar]
  41. Hertl M, Bohlen H, Jugert F, Merk HF. Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by β-lactam antibiotics. J Invest Dermatol 1993; 101: 794–9. [Google Scholar]
  42. Reilly TP, Lash LH, Doll MA, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164–73. [Google Scholar]
  43. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity questionnaire. Allergy 1999; 54: 999–1003. [Google Scholar]
  44. Brochow K, Romano A, Blanca M, Ring J, Pichler WJ, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2003 (sous presse). [Google Scholar]
  45. Barbaud A. Gonçalo M, Bruynzeel D, Bircher A. Guidelines for skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321–8. [Google Scholar]
  46. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985; 40: 111–4. [Google Scholar]
  47. Guilloux L, Ricard-Blum S, Ville G, Motin J. Histamine release assay and radioimmunoassay for the detection of IgE antibodies against neuromuscular blocking drugs. Ann Fr Anesth Reanim 1993; 12: 182–6. [Google Scholar]
  48. Lebel B, Messaad D, Kvedariene V, Rongier M, Bousquet J, Demoly P. Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions. Allergy 2001; 56: 688–92. [Google Scholar]
  49. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27: 175–81. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.